These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 9196609)

  • 1. Hypothalamic-pituitary-adrenal axis in abdominal obesity: effects of dexfenfluramine.
    Boushaki FZ; Rasio E; Serri O
    Clin Endocrinol (Oxf); 1997 Apr; 46(4):461-6. PubMed ID: 9196609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of the naloxone test with ovine CRH and insulin hypoglycaemia in the evaluation of the hypothalamic-pituitary-adrenal axis in normal man.
    Inder WJ; Ellis MJ; Evans MJ; Donald RA
    Clin Endocrinol (Oxf); 1995 Oct; 43(4):425-31. PubMed ID: 7586616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypothalamo-pituitary-adrenal axis dysfunction in chronic fatigue syndrome, and the effects of low-dose hydrocortisone therapy.
    Cleare AJ; Miell J; Heap E; Sookdeo S; Young L; Malhi GS; O'Keane V
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3545-54. PubMed ID: 11502777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of alcoholism on the hypothalamic-pituitary-adrenal axis: interaction with endogenous opioid peptides.
    Inder WJ; Joyce PR; Ellis MJ; Evans MJ; Livesey JH; Donald RA
    Clin Endocrinol (Oxf); 1995 Sep; 43(3):283-90. PubMed ID: 7586596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. alpha2-adrenoceptor regulation of the hypothalamic-pituitary-adrenocortical axis in obesity.
    Pasquali R; Vicennati V; Calzoni F; Gnudi U; Gambineri A; Ceroni L; Cortelli P; Menozzi R; Sinisi R; Rio GD
    Clin Endocrinol (Oxf); 2000 Apr; 52(4):413-21. PubMed ID: 10762283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Central obesity, depression and the hypothalamo-pituitary-adrenal axis in men and postmenopausal women.
    Katz JR; Taylor NF; Goodrick S; Perry L; Yudkin JS; Coppack SW
    Int J Obes Relat Metab Disord; 2000 Feb; 24(2):246-51. PubMed ID: 10702778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of body mass on the hypothalamic-pituitary-adrenal-axis response to naloxone in patients with polycystic ovary syndrome.
    Guido M; Ciampelli M; Fulghesu AM; Pavone V; Barini A; de Marinis L; Cento R; Caruso A; Lanzone A
    Fertil Steril; 1999 Mar; 71(3):462-7. PubMed ID: 10065783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypothalamic-pituitary-adrenal axis activity and its relationship to the autonomic nervous system in women with visceral and subcutaneous obesity: effects of the corticotropin-releasing factor/arginine-vasopressin test and of stress.
    Pasquali R; Anconetani B; Chattat R; Biscotti M; Spinucci G; Casimirri F; Vicennati V; Carcello A; Labate AM
    Metabolism; 1996 Mar; 45(3):351-6. PubMed ID: 8606643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abnormalities of the hypothalamic-pituitary-adrenal axis in nondepressed women with abdominal obesity and relations with insulin resistance: evidence for a central and a peripheral alteration.
    Vicennati V; Pasquali R
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4093-8. PubMed ID: 11095438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of chronic administration of the serotonin agonist dexfenfluramine on responsiveness to corticotropin releasing hormone and growth hormone-releasing hormone in moderately obese people.
    Drent ML; Adèr HJ; van der Veen EA
    J Endocrinol Invest; 1995 Nov; 18(10):780-8. PubMed ID: 8787955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-dexamethasone serum copeptin corresponds to HPA axis responsiveness in human obesity.
    Schinke C; Hesse S; Stoppe M; Meyer K; Schmidt E; Orthgiess J; Bechmann L; Bresch A; Rullmann M; Luthardt J; Sabri O; Blüher M; Kratzsch J; Then Bergh F
    Psychoneuroendocrinology; 2017 Apr; 78():39-47. PubMed ID: 28167369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response of the hypothalamic-pituitary-adrenal axis to small dose arginine-vasopressin and daily urinary free cortisol before and after alprazolam pre-treatment differs in obesity.
    Vicennati V; Ceroni L; Gagliardi L; Pagotto U; Gambineri A; Genghini S; Pasquali R
    J Endocrinol Invest; 2004 Jun; 27(6):541-7. PubMed ID: 15717651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aspirin increases the human hypothalamic-pituitary-adrenal axis response to naloxone stimulation.
    Hockings GI; Grice JE; Crosbie GV; Walters MM; Jackson AJ; Jackson RV
    J Clin Endocrinol Metab; 1993 Aug; 77(2):404-8. PubMed ID: 8393884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence of a disturbance of the hypothalamic-pituitary-adrenal axis in polycystic ovary syndrome: effect of naloxone.
    Lanzone A; Guido M; Ciampelli M; Fulghesu AM; Pavone V; Proto C; Caruso A; Mancuso S
    Clin Endocrinol (Oxf); 1996 Jul; 45(1):73-7. PubMed ID: 8796141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced circadian ACTH release in obese premenopausal women: reversal by short-term acipimox treatment.
    Kok P; Kok SW; Buijs MM; Westenberg JJ; Roelfsema F; Frölich M; Stokkel MP; Meinders AE; Pijl H
    Am J Physiol Endocrinol Metab; 2004 Nov; 287(5):E848-56. PubMed ID: 15280154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypothalamic amenorrhea: evidence for a central derangement of hypothalamic-pituitary-adrenal cortex axis activity.
    Nappi RE; Petraglia F; Genazzani AD; D'Ambrogio G; Zara C; Genazzani AR
    Fertil Steril; 1993 Mar; 59(3):571-6. PubMed ID: 8384575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serotoninergic receptor activation by dextrofenfluramine enhances the blunted pituitary-adrenal responsiveness to corticotropin-releasing hormone in obese subjects.
    Bernini GP; Argenio GF; Del Corso C; Vivaldi MS; Birindelli R; Franchi F
    Metabolism; 1992 Jan; 41(1):17-21. PubMed ID: 1311402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of stimulated and spontaneous adrenocorticotropin secretory dynamics identifies distinct components of cortisol feedback inhibition in healthy humans.
    Dorin RI; Ferries LM; Roberts B; Qualls CR; Veldhuis JD; Lisansky EJ
    J Clin Endocrinol Metab; 1996 Nov; 81(11):3883-91. PubMed ID: 8923833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gonadotropin-releasing hormone agonist in premenopausal women does not alter hypothalamic-pituitary-adrenal axis response to corticotropin-releasing hormone.
    Gavin KM; Shea KL; Gibbons E; Wolfe P; Schwartz RS; Wierman ME; Kohrt WM
    Am J Physiol Endocrinol Metab; 2018 Aug; 315(2):E316-E325. PubMed ID: 29631362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined dexamethasone suppression-corticotrophin-releasing hormone stimulation test in medication-free major depression and healthy volunteers.
    Sher L; Oquendo MA; Burke AK; Cooper TB; Mann JJ
    J Affect Disord; 2013 Dec; 151(3):1108-12. PubMed ID: 23866302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.